CRISPR-Cas9-mediated uATG introduction in the 5′UTR of the Uox gene for hyperuricemia mouse models: implications for gout and metabolic disorders
Key Points
Hyperuricemia significantly alters gout-related markers, indicating a potential treatment avenue.
In mouse models, CRISPR-Cas9 was employed to introduce uATG in the Uox gene, with implications for managing metabolic disorders.
Analysis of genetic interventions reveals promising results for understanding the pathology linked to gout.
These findings highlight the need for further exploration of genetic therapies and their impact on metabolic health.
Like
Bookmark
Share
Like
Bookmark
Share
CRISPR-Cas9-mediated uATG introduction in the 5′UTR of the Uox gene for hyperuricemia mouse models: implications for gout and metabolic disorders | Synapse